The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1195-1196 , December 2009

Pharmacogenetics of β2-agonists in children

  • Michael Kabesch, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Michael Kabesch, MD, Center for Pediatrics, Clinic for Pediatric Pneumology and Neonatology, Hannover Medical School, Carl-Neuberg-Str 1, D-30625 Hannover, Germany.

Received 15 September 2009 ,Accepted 15 September 2009.

References 

  1. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26
  2. Martinez FD. Safety of long-acting beta-agonists—an urgent need to clear the air. N Engl J Med. 2005;353:2637–2639
  3. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33:21–32
  4. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists—the influence of values. N Engl J Med. 2009;360:1592–1595
  5. Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting beta-agonists: urgent need to clear the air remains. Eur Respir J. 2009;33:3–5
  6. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med. 2009;360:1671–1672
  7. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55:762–767
  8. Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet. 2006;368:771–779
  9. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  10. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370:2118–2125
  11. Basu K, Palmer C, Tavendale R, Lipworth B, Mukhopadhyay S. Adrenergic beta2-receptor genotype predisposes to exacerbations in steroid-treated asthmatics on frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009;124:1188–1194

 Disclosure of potential conflict of interest: M. Kabesch has received reimbursement for lectures from or served on advisory boards for Roxall, Glaxo Wellcome, Novartis, Sanofi Aventis, and Allergopharma, and has received research support from the Deutsche Forschungsgemeinschaft, the Federal Ministry of Education and Research (BMBF), and the European Union.

PII: S0091-6749(09)01412-2

doi: 10.1016/j.jaci.2009.09.023

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1195-1196 , December 2009

Article Tools